{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:38:31Z","timestamp":1791563911015,"version":"4.3.4"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005362","name":"Universit\u00e0 degli Studi di Bari","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005362","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.coph.2022.102329","type":"journal-article","created":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T16:46:19Z","timestamp":1670690779000},"page":"102329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Drug repurposing in skeletal muscle ion channelopathies"],"prefix":"10.1016","volume":"68","author":[{"given":"Concetta","family":"Altamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Saltarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Campanale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Laghetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8816-9369","authenticated-orcid":false,"given":"Jean-Fran\u00e7ois","family":"Desaphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2022.102329_sref1","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3390\/cells10061521","article-title":"Ion Channel gene mutations causing skeletal muscle disorders: pathomechanisms and opportunities for therapy","volume":"10","author":"Maggi","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.coph.2022.102329_bib2","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1212\/WNL.0b013e31828cf8d0","article-title":"Prevalence study of genetically defined skeletal muscle channelopathies in England","volume":"80","author":"Horga","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.coph.2022.102329_bib3","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.nmd.2018.03.006","article-title":"Prevalence and mutation spectrum of skeletal muscle channelopathies in The Netherlands","volume":"28","author":"Stunnenberg","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.coph.2022.102329_sref4","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/mus.26887","article-title":"Guidelines on clinical presentation and management of nondystrophic myotonias","volume":"62","author":"Stunnenberg","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.coph.2022.102329_sref5","first-page":"37","article-title":"Understanding the impact of non-dystrophic myotonia on patients and caregivers: results from a burden of disease healthcare survey","volume":"6","author":"Diaz-Manera","year":"2021","journal-title":"Eur Med (Edicion Espanola) J"},{"key":"10.1016\/j.coph.2022.102329_sref6","first-page":"357","article-title":"Targeted therapies for skeletal muscle ion channelopathies: systematic review and steps towards precision medicine","volume":"8","author":"Desaphy","year":"2021","journal-title":"J\u00a0Neuromuscul Dis"},{"key":"10.1016\/j.coph.2022.102329_bib7","first-page":"49","article-title":"Int\u00e9r\u00eat de la mexil\u00e9tine dans le traitement de la myotonie de Thomsen-Becker [Value of mexiletine in the treatment of Thomsen-Becker myotonia]","volume":"43","author":"Leheup","year":"1986","journal-title":"Arch Fr Pediatr"},{"key":"10.1016\/j.coph.2022.102329_bib8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1600-0404.1992.tb05103.x","article-title":"Treatment of myotonia with antiarrhythmic drugs","volume":"86","author":"Kwieci\u0144ski","year":"1992","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.coph.2022.102329_bib9","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1651-2227.1992.tb12271.x","article-title":"Clinical and electrophysiological reports in a case of early onset myotonia congenita (Thomsen's disease) successfully treated with mexiletine","volume":"81","author":"Ceccarelli","year":"1992","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.coph.2022.102329_bib10","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/mus.880170710","article-title":"Paramyotonia congenita: abnormal short exercise test, and improvement after mexiletine therapy","volume":"17","author":"Jackson","year":"1994","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.coph.2022.102329_bib11","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1001\/jama.2012.12607","article-title":"Consortium for Clinical Investigation of Neurologic Channelopathies: mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial","volume":"308","author":"Statland","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2022.102329_bib12","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1001\/jama.2018.18020","article-title":"Effect of mexiletine\u00a0on\u00a0muscle stiffness in patients with nondystrophic\u00a0myotonia\u00a0evaluated using aggregated N-of-1 trials","volume":"320","author":"Stunnenberg","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2022.102329_sref13","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.nmd.2021.06.010","article-title":"Efficacy and safety of mexiletine in non-dystrophic myotonias: a randomised, double-blind, placebo-controlled, cross-over study","volume":"31","author":"Vicart","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.coph.2022.102329_bib14","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jamaneurol.2015.2338","article-title":"Long-term safety and efficacy of mexiletine for patients with skeletal muscle channelopathies","volume":"72","author":"Suetterlin","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.coph.2022.102329_sref15","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3389\/fneur.2020.00300","article-title":"Long-term safety and usefulness of mexiletine in a large cohort of patients affected by non-dystrophic myotonias","volume":"11","author":"Modoni","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.coph.2022.102329_bib16","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ana.24331","article-title":"Sodium channel slow inactivation as a therapeutic target for myotonia congenita","volume":"77","author":"Novak","year":"2015","journal-title":"Ann Neurol"},{"key":"10.1016\/j.coph.2022.102329_bib17","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.0000000000004229","article-title":"Open-label trial of ranolazine for the treatment of myotonia congenita","volume":"89","author":"Arnold","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.coph.2022.102329_sref18","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/mus.26372","article-title":"Open-label trial of ranolazine for the treatment of paramyotonia congenita","volume":"59","author":"Lorusso","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.coph.2022.102329_bib19","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mus.25452","article-title":"The anti-convulsants lacosamide, lamotrigine, and rufinamide reduce myotonia in isolated human and rat skeletal muscle","volume":"56","author":"Skov","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.coph.2022.102329_bib20","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1093\/brain\/awx192","article-title":"The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study","volume":"140","author":"Andersen","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.coph.2022.102329_bib21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.neuropharm.2012.09.006","article-title":"In\u00a0vivo evaluation of antimyotonic efficacy of \u03b2-adrenergic drugs in a rat model of myotonia","volume":"65","author":"Desaphy","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.coph.2022.102329_bib22","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.expneurol.2014.02.023","article-title":"Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs","volume":"255","author":"Desaphy","year":"2014","journal-title":"Exp Neurol"},{"key":"10.1016\/j.coph.2022.102329_bib23","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.neuropharm.2016.10.013","article-title":"Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in\u00a0vivo antimyotonic activity","volume":"113","author":"De Bellis","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.coph.2022.102329_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2020.113287","article-title":"Safinamide's potential in treating nondystrophic myotonias: inhibition of skeletal muscle voltage-gated sodium channels and skeletal muscle hyperexcitability in\u00a0vitro and in\u00a0vivo","volume":"328","author":"Desaphy","year":"2020","journal-title":"Exp Neurol"},{"key":"10.1016\/j.coph.2022.102329_bib25","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00228-012-1414-3","article-title":"Dramatic improvement of myotonia permanens with flecainide: a two-case report of a possible bench-to-bedside pharmacogenetics strategy","volume":"69","author":"Desaphy","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.coph.2022.102329_bib26","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1212\/WNL.0000000000002721","article-title":"Translational approach to address therapy in myotonia permanens due to a new SCN4A mutation","volume":"86","author":"Desaphy","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.coph.2022.102329_bib27","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-3289","article-title":"Flecainide-responsive myotonia permanens with SNEL onset: a new case and literature review","volume":"137","author":"Portaro","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.coph.2022.102329_bib28","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.phrs.2019.01.004","article-title":"Pharmacogenetics of myotonic hNav1.4 sodium channel variants situated near the fast inactivation gate","volume":"141","author":"Farinato","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.coph.2022.102329_bib29","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/jnnp-2017-317615","article-title":"Successful long-term therapy with flecainide in a family with paramyotonia congenita","volume":"89","author":"Terracciano","year":"2018","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.coph.2022.102329_bib30","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00424-020-02376-3","article-title":"Skeletal muscle ClC-1 chloride channels in health and diseases","volume":"472","author":"Altamura","year":"2020","journal-title":"Pfl\u00fcgers Archiv"},{"key":"10.1016\/j.coph.2022.102329_sref31","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2021.113758","article-title":"Increased sarcolemma chloride conductance as one of the mechanisms of action of carbonic anhydrase inhibitors in muscle excitability disorders","volume":"342","author":"Altamura","year":"2021","journal-title":"Exp Neurol"},{"key":"10.1016\/j.coph.2022.102329_bib32","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/mus.20585","article-title":"Acetazolamide acts directly on the human skeletal muscle chloride channel","volume":"34","author":"Eguchi","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.coph.2022.102329_bib33","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/sj.bjp.0706954","article-title":"Niflumic acid inhibits chloride conductance of rat skeletal muscle by directly inhibiting the CLC-1 channel and by increasing intracellular calcium","volume":"150","author":"Liantonio","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.coph.2022.102329_bib34","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1111\/bph.14192","article-title":"Mapping ligand binding pockets in chloride ClC-1 channels through an integrated in silico and experimental approach using anthracene-9-carboxylic acid and niflumic acid","volume":"175","author":"Altamura","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.coph.2022.102329_sref35","doi-asserted-by":"crossref","first-page":"958196","DOI":"10.3389\/fphar.2022.958196","article-title":"Chaperone activity of niflumic acid on ClC-1 chloride channels mutants causing myotonia congenita","volume":"13","author":"Altamura","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coph.2022.102329_bib36","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/mus.26009","article-title":"Review of the diagnosis and treatment of periodic paralysis","volume":"57","author":"Statland","year":"2018","journal-title":"Muscle Nerve"},{"issue":"10","key":"10.1016\/j.coph.2022.102329_sref37","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11940-020-00644-2","article-title":"Treatment updates for neuromuscular channelopathies","volume":"22","author":"Jitpimolmard","year":"2020","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.coph.2022.102329_bib38","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.braindev.2020.10.010","article-title":"Familial periodic paralysis associated with a rare KCNJ5 variant that supposed to have incomplete penetrance","volume":"43","author":"Hiraide","year":"2021","journal-title":"Brain Dev"},{"key":"10.1016\/j.coph.2022.102329_bib39","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.1210\/jc.2019-00672","article-title":"Contribution of asian haplotype of KCNJ18 to susceptibility to and ethnic differences in thyrotoxic periodic paralysis","volume":"104","author":"Noso","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.coph.2022.102329_bib40","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1056\/NEJM196803142781102","article-title":"Acetazolamide prophylaxis in hypokalemic periodic paralysis","volume":"278","author":"Resnick","year":"1968","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102329_bib41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.nmd.2005.10.005","article-title":"Carbonic anhydrase inhibitors ameliorate the symptoms of hypokalaemic periodic paralysis in rats by opening the muscular Ca2+- activated K+ channels","volume":"16","author":"Tricarico","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.coph.2022.102329_bib42","first-page":"CD005045","article-title":"Treatment for periodic paralysis","volume":"1","author":"Sansone","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.coph.2022.102329_bib43","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1212\/WNL.0b013e31823a0cb6","article-title":"Acetazolamide efficacy in hypokalemic periodic paralysis and the predictive role of genotype","volume":"77","author":"Matthews","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.coph.2022.102329_bib44","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/1531-8249(200001)47:1<46::AID-ANA9>3.0.CO;2-H","article-title":"Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis","volume":"47","author":"Tawil","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.coph.2022.102329_bib45","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0000000000002416","article-title":"Muscle Study Group: randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis","volume":"86","author":"Sansone","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.coph.2022.102329_sref46","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/mus.27354","article-title":"Long-term efficacy and safety of dichlorphenamide for treatment of primary periodic paralysis","volume":"64","author":"Sansone","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.coph.2022.102329_bib47","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1212\/WNL.0b013e3182886a0e","article-title":"Bumetanide prevents transient decreases in muscle force in murine hypokalemic periodic paralysis","volume":"80","author":"Wu","year":"2013","journal-title":"Neurology"},{"issue":"Pt 12","key":"10.1016\/j.coph.2022.102329_bib48","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1093\/brain\/awt280","article-title":"Beneficial effects of bumetanide in a CaV1.1-R528H mouse model of hypokalaemic periodic paralysis","volume":"136","author":"Wu","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.coph.2022.102329_bib49","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1113\/jphysiol.2001.013298","article-title":"Effects of chloride transport on bistable behaviour of the membrane potential in mouse skeletal muscle","volume":"542","author":"Geukes Foppen","year":"2002","journal-title":"J\u00a0Physiol"},{"key":"10.1016\/j.coph.2022.102329_bib50","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/jnnp.65.2.248","article-title":"Salbutamol treatment in a patient with hyperkalaemic periodic paralysis due to a mutation in the skeletal muscle sodium channel gene (SCN4A)","volume":"65","author":"Hanna","year":"1998","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.coph.2022.102329_bib51","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1085\/jgp.201010586","article-title":"Na+,K+-pump stimulation improves contractility in isolated muscles of mice with hyperkalemic periodic paralysis","volume":"138","author":"Clausen","year":"2011","journal-title":"J\u00a0Gen Physiol"},{"key":"10.1016\/j.coph.2022.102329_sref52","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1136\/jnnp-2021-326347","article-title":"N-of-1 trial of salbutamol in hyperkalaemic periodic paralysis","volume":"92","author":"Stunnenberg","year":"2021","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.coph.2022.102329_bib53","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/jama.2012.12906","article-title":"Mexiletine for treatment of myotonia: a trial triumph for rare disease networks","volume":"308","author":"Hoffman","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2022.102329_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drudis.2018.06.012","article-title":"Renovation as innovation: is repurposing the future of drug discovery research?","volume":"24","author":"Neuberger","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.coph.2022.102329_bib55","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1136\/jnnp-2019-320879","article-title":"Drug repurposing in neurological diseases: an integrated approach to reduce trial and error","volume":"90","author":"Clout","year":"2019","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.coph.2022.102329_sref56","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jval.2021.02.004","article-title":"Cost-based price calculation of mexiletine for nondystrophic myotonia","volume":"24","author":"van den Berg","year":"2021","journal-title":"Value Health"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489222001564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489222001564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:57:20Z","timestamp":1761461840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489222001564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":56,"alternative-id":["S1471489222001564"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2022.102329","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug repurposing in skeletal muscle ion channelopathies","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2022.102329","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102329"}}